Sagent launches new heart injection
SCHAUMBURG - Sagent Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia - a potentially life-threatening irregular heart beat. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $8 million.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.